Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered...
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page